High Flow Nasal Cannula Versus Bubble Nasal CPAP for the Treatment of Transient Tachypnea of the Newborn in Infants ≥ 35 Weeks Gestation

Stopped early · Not applicable

Conditions studied: Transient Tachypnea of the Newborn

In brief

The primary objective is to determine whether High Flow Nasal Cannula (HFNC) is a superior respiratory modality for neonates ≥36 weeks with transient tachypnea of the newborn (TTN) when compared to the standard of care modality (NCPAP).

Key facts

Study ID

NCT01270581

Run by

Icahn School of Medicine at Mount Sinai

People needed

7

Starts

2010-07-01

Expected to finish

2012-04-01

Last updated by the study team

2017-02-16

Who can join

Age: any, up to 0. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• gestational age ≥ 35 weeks
• diagnosis of TTN, defined as respiratory rate >60, presence of subcostal and /or intercostal retractions, nasal flaring, grunting, oxygen saturations 70-93% on room air, and radiological evidence of perihilar streaking and patchy infiltrates
• admission to the NICU at Mount Sinai hospital within first 24 hours of life

You may not qualify if…

• gestational age < 35 weeks
• history of thick meconium stained fluid and/or diagnosis of meconium aspiration syndrome
• diagnosis of major congenital pulmonary or cardiac anomalies
• initial CXR demonstrating air leak
• respiratory distress first occurring after 24 hours of life
• presumptive diagnosis of RDS as indicated by the need for FiO2 > 40%, severe retractions and grunting with poor air entry, and diffuse alveolar consolidation on chest radiograph

Where it is running

• Mount Sinai School of Medicine — New York, New York, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.